Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

High-dose therapy in acute leukemia

C Carlo-Stella1, L Mangoni, C Caramatti

  • 1Department of Hematology and Bone Marrow Transplantation Unit, University of Parma, Italy.

Leukemia & Lymphoma
|May 7, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recurrence-specific supervised graph clustering for subtyping Hodgkin Lymphoma radiomic phenotypes.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2021
Same author

Correction to: Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma.

European journal of nuclear medicine and molecular imaging·2021
Same author

Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma.

European journal of nuclear medicine and molecular imaging·2020
Same author

Early consolidation with high-dose therapy and autologous stem cell transplantation is a feasible and effective treatment option in HIV-associated non-Hodgkin lymphoma at high risk.

Bone marrow transplantation·2017
Same author

Circulating endothelial cell count: a reliable marker of endothelial damage in patients undergoing hematopoietic stem cell transplantation.

Bone marrow transplantation·2017
Same author

Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma.

Bone marrow transplantation·2017
Same journal

Leukemia mortality analysis in the pediatric population in São Paulo state, Brazil, 2000-2019.

Leukemia & lymphoma·2026
Same journal

CPX‑351 vs. FLAG‑ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trial.

Leukemia & lymphoma·2026
Same journal

Specialist palliative care access and end-of-life hospitalizations in acute leukemia: a nationwide register study.

Leukemia & lymphoma·2026
Same journal

D-VRD vs. D-KRD induction in transplant-eligible multiple myeloma: a real-world comparison.

Leukemia & lymphoma·2026
Same journal

T-box factor EOMES is part of an aberrant network in Hodgkin lymphoma.

Leukemia & lymphoma·2026
Same journal

Overall survival of patients with chronic lymphocytic leukemia treated with venetoclax-obinutuzumab compared to age- and sex-matched general population.

Leukemia & lymphoma·2026
See all related articles

Intensive chemotherapy achieves high remission rates for acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), but cure rates remain low. Post-remission strategies like stem cell transplantation are crucial for improving survival in young adults.

Area of Science:

  • Hematology
  • Oncology
  • Stem Cell Transplantation

Background:

  • Intensive induction chemotherapy, including anthracycline and cytarabine combinations, yields >70% complete remission rates in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).
  • Current standard-dose therapies result in only 20% cure rates for young adults with these leukemias.
  • Effective post-remission strategies are essential to significantly increase cure rates.

Purpose of the Study:

  • To evaluate the efficacy of different post-remission therapeutic options for AML and ALL.
  • To determine the optimal strategy for increasing cure rates in young adults with leukemia.
  • To assess the role of stem cell transplantation in improving leukemia-free survival.

Main Methods:

  • Review of randomized trials comparing dose-intensified chemotherapy, allogeneic stem cell transplantation, and autologous stem cell transplantation.

Related Experiment Videos

  • Evaluation of prognostic factors including cytogenetic, molecular, and phenotypic characteristics.
  • Analysis of outcomes based on different therapeutic interventions.

    • Main Results:

    • Randomized trials confirm improved leukemia-free survival with both allogeneic and autologous stem cell transplantation.
    • Autologous stem cell transplantation demonstrates significant promise as a treatment modality for AML.
    • Further investigation is needed to define the optimal methods and role of stem cell transplantation in adult ALL.

    Conclusions:

    • Post-remission therapy, particularly stem cell transplantation, is critical for improving cure rates in AML and ALL.
    • Autologous stem cell transplantation is a highly promising approach for AML, with preparative regimens and purging techniques being key factors.
    • The optimal application of stem cell transplantation in adult ALL requires further research.